article thumbnail

Innovative Data Featuring Nanox AI Cardiac Solution Showcased at SCCT 2024

DAIC

mtaschetta-millane Thu, 07/25/2024 - 08:55 July 25, 2024 — Nanox, an innovative medical imaging technology company, announced that the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox.AI was highlighted in multiple scientific presentations at the 2024 Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting. “We

article thumbnail

American Heart Month Puts Spotlight on Cardiovascular Disease and Stroke Statistics

DAIC

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. percent Compound Annual Growth Rate (CAGR).

article thumbnail

Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis

Frontiers in Cardiovascular Medicine

These innovative strategies hold promise for improving the management of atherosclerosis in the near future. Based on these mechanisms, we discuss novel therapeutic approaches that have been developed to regulate the generation of intimal foam-like cells.

article thumbnail

Cleerly Launches Cleerly ISCHEMIA Solution for Heart Disease Analysis

DAIC

Through its AI capability, Cleerly ISCHEMIA determines the likely presence or absence of coronary vessel ischemia based on quantitative measures of atherosclerosis, stenosis, and significant vascular morphology from patients’ CCTA images. We are proud to support healthcare professionals personalize patients' heart health journeys.

Ischemia 119
article thumbnail

Roche's Lp(a) Gen.2 Molarity Assay Receives FDA Clearance

DAIC

Roche has an unrivaled ability to provide access to testing at scale and is committed to advancing innovation in preventive cardiology. For more information, please visit www.roche.com. Tsimikas S and Marcovina S, Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week , J Am Coll Cardiol.

article thumbnail

The Cardiometabolic Event of the Year: What to Expect at the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

This fall, we come together for the largest and most innovative cardiometabolic event in honor of the legacy of Dr. George L. Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease.

Education 100
article thumbnail

Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

DAIC

The CAD Staging System is a noninvasive imaging-based investigational software device that analyzes important and actionable features of coronary atherosclerosis, stenosis and ischemia. Cleerly’s mission extends beyond innovation; it is a commitment to saving lives by revolutionizing the prevention and treatment of heart disease.